Cleveland BioLabs CBLI shares are trading higher on Tuesday after the company, along with Cytocom, announced they have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.
Cleveland BioLabs is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology.
Cleveland BioLabs shares traded up 90.78% to $4.14 on Tuesday. The stock has a 52-week high of $5.43 and a 52-week low of 50 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
